BLASUBCUTANEOUSVIAL
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
KINERET (anakinra) by Swedish Orphan Biovitrum is interleukin 1 receptor antagonists [moa]. First approved in 2001.
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KINERET (anakinra) is an interleukin-1 receptor antagonist administered subcutaneously as a vial injection. It blocks IL-1 signaling to reduce inflammatory responses in autoimmune and autoinflammatory conditions. The drug has been approved since 2001 and is now approaching loss of exclusivity.
$0.028BPart D
LOE ApproachingProduct is in LOE phase with modest Part D utilization; commercial team likely focused on defending market share and managing transition.
Mechanism of Action
Interleukin 1 Receptor Antagonists
Pharmacologic Class:
Interleukin-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
Started Mar 2026
0Familial Mediterranean Fever (FMF )
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
Started Sep 2025
30 enrolled
Cryopyrin-Associated Periodic SyndromesAmyloidosis
An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)
Started Sep 2025
0Systemic Juvenile Idiopathic Arthritis (sJIA)Adult Onset Still's Disease (AOSD)
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
Started Oct 2023
84 enrolled
Kawasaki Disease
A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
Started Dec 2022
33 enrolled
Cystic Fibrosis, 10011762
Worked on KINERET at Swedish Orphan Biovitrum? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.